Gastric Cancer Content
Jean-Luc Van Laethem, ESMO 2021: Updated Results of the Phase II KEYNOTE-224 Study
touchONCOLOGY joins Professor Jean-Luc Van Laethem (Erasme University Hospital, Brussels, Belgium), principle investigator of the KEYNOTE-224 study, to discuss the updated results for pembrolizumab monotherapy as first-line therapy for advanced hepatocellular carcinoma. Questions 1. What were the objectives of the KEYNOTE-224 study? (00:38-01:33) 2. What have previous study findings taught us about the clinical utility […]
Yelena Y Janjigian, ASCO 2021: Durvalumab in Gastric Cancer and the MATTERHORN Study
touchONCOLOGY joins Dr Yelena Janjigian (Medical Oncologist, Chief, Memorial Sloan Kettering Cancer Center, New York, NY, USA) at ASCO 2021 to discuss durvalumab in gastric cancer and the MATTERHORN study. The abstract ‘A phase Ib/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!